Safety Of 300IR 5-Grass Tablet In Grass Pollen –Allergic Children With Or Without Controlled Asthma: Further Data From A Post-Marketing Observational Study

We report safety data of 300IR 5-grass tablet* for patient subgroups with/without controlled asthma in a post-marketing study of children (aged 5-9 years) with grass pollen –induced allergic rhinitis/rhinoconjunctivitis (GP-AR). (Source: Journal of Allergy and Clinical Immunology)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2TJCAji